Loading
A phase 1/2 trial of KSQ-004EX run by M.D. Anderson Cancer Center, now recruiting.
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06598371 by M.D. Anderson Cancer Center, with 141 participants planned, started 2024-11-21, primary completion expected 2039-08-01. Conditions recorded: Select Advanced Solid Tumors. Interventions recorded: Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ Therapeutics and the tag pipeline.
Shares KSQ-004EX, KSQ Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/